Cormorant Asset Management, LP describes itself as a life sciences and healthcare focused investment firm, founded by Bihua Chen in 2013, that primarily invests in biotechnology companies across the public and private markets. It says it employs a long-term, fundamental and research-intensive approach grounded in deep scientific and therapeutic analysis, and that it seeks to understand drugs, technologies, business models and competitive landscapes. The IPO prospectus of Helix Acquisition Corp. III, a special purpose acquisition company whose sponsor is a Cormorant affiliate, states that since its inception in 2013 Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. The firm is registered with the SEC as an investment adviser, files quarterly Form 13F-HR reports on its US-listed long positions, and runs a series of private funds alongside its public strategy: Cormorant Global Healthcare Master Fund, LP and Cormorant Private Healthcare Fund II, III, IV, V and VI, LP.
Over $2.4B (assets under management as of 30 September 2025, as stated in the Helix Acquisition Corp. III IPO prospectus, Form 424B4 filed 23 January 2026; the firm's Form ADV Item 5.F figure could not be read) AUM79/100 Power Score™2013 FoundedBoston, MA
Bihua Chen founds Cormorant Asset Management in Boston.
2017
The firm's SEC filings change from Cormorant Asset Management, LLC to Cormorant Asset Management, LP: the 13F-HR for the quarter ended 31 March 2017 was filed under the LLC name and the 13F-HR for the quarter ended 30 September 2017 under the LP name.
2026
Helix Acquisition Corp. III, a special purpose acquisition company whose sponsor is a Cormorant affiliate and whose Chairperson and CEO is Bihua Chen, completes its IPO (Form 424B4 filed 23 January 2026); the prospectus states Cormorant had over $2.4 billion in assets under management as of 30 September 2025.